DelveInsight's Antiphospholipid Syndrome (APS) - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Antiphospholipid Syndrome (APS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Antiphospholipid Syndrome (APS) Epidemiology Forecast | Antiphospholipid Syndrome (APS) Prevalent population

<h2 class="MsoNormal">Key Highlights</h2>
<ul>
<li class="MsoNormal">Antiphospholipid syndrome (APS) is an autoimmune disorder where the immune system mistakenly produces abnormal antibodies called antiphospholipid antibodies, which target proteins attached to fat molecules, making blood more likely to clot in arteries and veins.</li>
<li class="MsoNormal">APS can lead to severe complications such as strokes, heart attacks, and obstetric/pregnancy-related issues like miscarriages and stillbirths.</li>
<li class="MsoNormal">aPLs are autoantibodies that target phospholipid-bound proteins, notably &szlig;2-glycoprotein-I (&szlig;2GPI).</li>
<li class="MsoNormal">It is commonly categorized into primary APS, known as Hughes syndrome, and secondary APS, linked to another systemic inflammatory rheumatic disease.</li>
<li class="MsoNormal">Signs and symptoms of APS include high blood pressure, deep vein thrombosis (DVT), strokes or transient ischemic attacks (TIAs), heart attacks, and pulmonary embolism (blockage in lung blood vessels).</li>
<li class="MsoNormal">APS is one of the few clinical conditions in which patients can present with both venous and arterial thrombosis, with deep vein thrombosis of the lower extremity the most common presentation and stroke the most common arterial manifestation. Recurrent pregnancy loss is the most common pregnancy-related complication.</li>
<li class="MsoNormal">The risk factors include autoimmune diseases like systemic lupus erythematosus, genetic predisposition, certain infections, female gender, age, pregnancy, atherosclerosis, heart disease, diabetes, etc. While specific triggers remain unclear, these factors are associated with an increased likelihood of developing APS.</li>
<li class="MsoNormal">The diagnosis of APS involves a combination of clinical evaluation and laboratory tests. Key criteria include the presence of antiphospholipid antibodies (aPL) and a history of characteristic clinical manifestations such as thrombosis or pregnancy complications. Diagnostic tests may include assays for aPL, lupus anticoagulant, and anticardiolipin antibodies. The complexity and variability of APS often require a multidisciplinary approach, considering both clinical and laboratory findings for accurate diagnosis and subsequent management.</li>
<li class="MsoNormal">APS mostly affects women between 30 and 40 years. In APS, abnormal proteins can cause the formation of clots in veins and arteries.</li>
<li class="MsoNormal">Total prevalent cases of antiphospholipid syndrome in the 7MM were approximately 300,000 in 2023, which is likely to increase at a CAGR of 0.4% during the study period (2021-2034).</li>
<li class="MsoNormal">Unfortunately, the clinical variability of APS, coupled with the absence of standardized diagnostic tests, contributes to its frequent underdiagnosis. The lack of a uniform approach to diagnosis may result in delayed identification and intervention, emphasizing the need for improved diagnostic tools and awareness to address this challenge in clinical practice.</li>
</ul>
&nbsp;
DelveInsight&rsquo;s &ldquo;Antiphospholipid Syndrome (APS) &ndash; Epidemiology Forecast &ndash; 2034&rdquo; report delivers an in-depth understanding of APS, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The table given below further depicts the key segments provided in the report:

<div dir="ltr" style="margin-left: 0pt;" align="center">
<table style="border: none; border-collapse: collapse;"><colgroup><col width="162" /><col width="462" /></colgroup>
<tbody>
<tr style="height: 0pt;">
<td style="vertical-align: middle; background-color: #ffffff; padding: 0pt 5.75pt 0pt 5.75pt; overflow: hidden; overflow-wrap: break-word; border: solid #808080 0.5pt;">
<span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Study Period
</td>
<td style="vertical-align: middle; background-color: #ffffff; padding: 0pt 5.75pt 0pt 5.75pt; overflow: hidden; overflow-wrap: break-word; border: solid #808080 0.5pt;">
<span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">2021-2034
</td>
</tr>
<tr style="height: 0pt;">
<td style="vertical-align: middle; background-color: #ffffff; padding: 0pt 5.75pt 0pt 5.75pt; overflow: hidden; overflow-wrap: break-word; border: solid #808080 0.5pt;">
<span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Forecast Period
</td>
<td style="vertical-align: middle; background-color: #ffffff; padding: 0pt 5.75pt 0pt 5.75pt; overflow: hidden; overflow-wrap: break-word; border: solid #808080 0.5pt;">
<span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">2024&ndash;2034
</td>
</tr>
<tr style="height: 0pt;">
<td style="vertical-align: middle; background-color: #ffffff; padding: 0pt 5.75pt 0pt 5.75pt; overflow: hidden; overflow-wrap: break-word; border: solid #808080 0.5pt;">
<span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Geographies Covered
</td>
<td style="vertical-align: middle; background-color: #ffffff; padding: 0pt 5.75pt 0pt 5.75pt; overflow: hidden; overflow-wrap: break-word; border: solid #808080 0.5pt;">
<span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan
</td>
</tr>
<tr style="height: 0pt;">
<td style="vertical-align: middle; background-color: #ffffff; padding: 0pt 5.75pt 0pt 5.75pt; overflow: hidden; overflow-wrap: break-word; border: solid #808080 0.5pt;">
<span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Epidemiology
</td>
<td style="vertical-align: middle; background-color: #ffffff; padding: 0pt 5.75pt 0pt 5.75pt; overflow: hidden; overflow-wrap: break-word; border: solid #808080 0.5pt;">
<span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Segmented by:
<ul>
<li dir="ltr" style="line-height: 1.38; text-align: justify;" role="presentation"><span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Prevalent Cases of Antiphospholipid Syndrome</li>
<li dir="ltr" style="line-height: 1.38; text-align: justify;" role="presentation"><span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Diagnosed Cases of Antiphospholipid Syndrome</li>
<li dir="ltr" style="line-height: 1.38; text-align: justify;" role="presentation"><span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Age-specific Cases</li>
<li dir="ltr" style="line-height: 1.38; text-align: justify;" role="presentation"><span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Gender-specific Cases</li>
<li dir="ltr" style="line-height: 1.38; text-align: justify;" role="presentation"><span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Type-specific Cases</li>
<li dir="ltr" style="line-height: 1.38; text-align: justify;" role="presentation"><span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Clinical manifestation-specific Cases</li>
<li dir="ltr" style="line-height: 1.38; text-align: justify;" role="presentation"><span style="font-size: 10pt; font-family: Arial,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Treated Cases</li>
</ul>
</td>
</tr>
</tbody>
</table>
</div>
<h2 class="MsoNormal">APS Disease Understanding and Diagnostic Algorithm</h2>
APS Overview
APS is a rare, immune-mediated, acquired hypercoagulable disorder characterized by the presence of persistent antiphospholipid antibodies (aPL) in combination with clinical events of thrombosis in the venous, arterial or microvascular system and/or certain adverse pregnancy outcomes. aPLs are autoantibodies that target phospholipid-bound proteins, notably &szlig;2-glycoprotein-I (&szlig;2GPI). Although the presence of these antibodies is the defining feature of this syndrome, the mechanism by which aPLs result in a hypercoagulable state remains incompletely understood.
&nbsp;
Other common non-criteria APS manifestations include thrombocytopenia, livedo reticularis, or cardiac valve thickening or dysfunction. The aPL that is included in the standard test panel are lupus anticoagulant, anticardiolipin antibody (aCL), and anti-&szlig;2 glycoprotein-I antibodies (anti-&szlig;2GPI).
&nbsp;
APS was first described by Professor Graham Hughes in 1983. It is usually divided into two groups: primary APS, also named Hughes syndrome, and secondary APS, associated with another systemic inflammatory rheumatic disease. Approximately 50% of patients with APS have a secondary form in association with an inflammatory disease, most commonly systemic lupus erythematosus (SLE). It has been shown that up to 10% of patients with primary APS are diagnosed with SLE within 10 years and redefined as secondary APS.
Further details are provided in the report&hellip;
&nbsp;
APS Diagnosis
Antiphospholipid Syndrome (APS) poses challenges in diagnosis due to its clinical variability and lack of standardized tests. Classification criteria, requiring clinical and laboratory criteria, aid in diagnosis but may exclude non-criteria manifestations.
&nbsp;
Additional antibodies like IgA aCL, anti-b2GPI, and others, though recognized, are not included in the current criteria. Diagnostic tests include ELISA for cardiolipin and b2GPI antibodies and the Lupus Anticoagulant (LA) test, performed according to International Society on Thrombosis and Hemostasis guidelines. LA is associated with venous thrombosis and stroke, while aCL is linked to pregnancy morbidity. Complication risks increase with the number of positive antibodies, with triple positivity (LA, aCL, and anti-b2GPI) indicating the highest risk. Early recognition and treatment are crucial for reducing APS-related mortality and morbidity.
Further details related to country-based variations are provided in the report&hellip;
<h2 class="MsoNormal">APS Epidemiology</h2>
The APS epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Antiphospholipid Syndrome, Diagnosed Cases of Antiphospholipid Syndrome, Age-specific Cases, Gender-specific Cases, Type-specific Cases, Clinical manifestation-specific Cases, Treated Cases in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2021 to 2034.
<ul>
<li class="MsoNormal">In the US, there were nearly 80,000 and ~41,000 cases of primary and secondary antiphospholipid syndrome in 2023, respectively, which is anticipated to increase by 2034.</li>
<li class="MsoNormal">In EU4 and the UK, out of all age groups, the highest number of age-specific cases accounted for 18&ndash;44 years, followed by 55&ndash;64 years and =75 years in 2023. In contrast, the least age-specific cases were observed in 65&ndash;74 years age groups.</li>
<li class="MsoNormal">As per DelveInsight&rsquo;s analysis, higher cases were observed for thrombotic than obstetric based on clinical manifestation-specific cases of symptomatic antiphospholipid syndrome throughout the 7MM countries.</li>
<li class="MsoNormal">In Japan, there were around 24,000 treated cases of antiphospholipid syndrome in 2023. These cases are likely to rise by 2034.</li>
</ul>
<h2 class="MsoNormal">Scope of the Report</h2>
<ul>
<li class="MsoNormal">The report covers a segment of key events, an executive summary, and a descriptive overview of APS, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.</li>
<li class="MsoNormal">Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.</li>
<li class="MsoNormal">A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.</li>
</ul>
<h2 class="MsoNormal">APS Report Insights</h2>
<ul>
<li class="MsoNormal">Patient Population</li>
<li class="MsoNormal">Prevalent Cases of Antiphospholipid Syndrome, Diagnosed Cases of Antiphospholipid Syndrome, Age-specific Cases, Gender-specific Cases, Type-specific Cases, Clinical manifestation-specific Cases, Treated Cases of Antiphospholipid Syndrome</li>
<li class="MsoNormal">Country-wise Epidemiology Distribution</li>
</ul>
<h2 class="MsoNormal">APS Report Key Strengths</h2>
<ul>
<li class="MsoNormal">Eleven-year Forecast</li>
<li class="MsoNormal">The 7MM Coverage</li>
<li class="MsoNormal">APS Epidemiology Segmentation</li>
</ul>
<h2 class="MsoNormal">APS Report Assessment</h2>
<ul>
<li class="MsoNormal">Epidemiology Segmentation</li>
<li class="MsoNormal">Current Diagnostic Practices</li>
</ul>
<h2 class="MsoNormal">Key Questions</h2>
Epidemiology Insights
<ul>
<li class="MsoNormal">What are the disease risks, burdens, and unmet needs of APS? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to APS?</li>
<li class="MsoNormal">What is the historical and forecasted APS patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?</li>
<li class="MsoNormal">What is the diagnostic pattern of APS?</li>
<li class="MsoNormal">Which clinical factors will affect APS?</li>
<li class="MsoNormal">Which factors will affect the increase in the diagnosis of APS?</li>
</ul>
<h2 class="MsoNormal">Reasons to buy</h2>
<ul>
<li class="MsoNormal">Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.</li>
<li class="MsoNormal">To understand the change in APS cases in varying geographies over the coming years.</li>
<li class="MsoNormal">Detailed overview on total hematopoietic stem-cell transplant cases, total allogeneic transplant cases, type of APS (acute and chronic), total incident cases of aAPS by grading and organ involvement, total 5-year prevalent cases of cAPS by grading and organ involvement, total treated patients of APS, mortality adjusted APS treated patients of APS is included.</li>
<li class="MsoNormal">To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.</li>
<li class="MsoNormal">Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.</li>
</ul>

1. Key Insights
2. Report Introduction
3. Antiphospholipid Syndrome (APS) Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of APS by Type in 2023
3.2. Patient Share (%) Distribution of APS by Manifestation in 2023
4. Executive Summary of Antiphospholipid Syndrome (APS)
5. Disease Background and Overview
5.1. Introduction
5.2. Signs and symptoms
5.3. Causes and Risk Factors
5.4. Clinical Manifestation of Antiphospholipid Syndrome
5.5. Pathophysiology of Antiphospholipid Syndrome
5.6. Classification of Antiphospholipid Syndrome
5.7. Diagnosis
5.7.1. Differential Guidelines
5.7.2. Diagnostic algorithm
6. Epidemiology Methodology
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Prevalent Cases of Antiphospholipid Syndrome in the 7MM
7.4. Diagnosed Cases of Antiphospholipid Syndrome in the 7MM
7.5. The United States
7.5.1. Diagnosed Cases of Antiphospholipid Syndrome in the United States
7.5.2. Age-specific Cases of Antiphospholipid Syndrome in the United States
7.5.3. Gender-specific Cases of Antiphospholipid Syndrome in the United States
7.5.4. Type-specific Cases of Antiphospholipid Syndrome in the United States
7.5.5. Clinical Manifestation-specific Cases of Antiphospholipid Syndrome in the United States
7.5.6. Treated Cases of Antiphospholipid Syndrome in the United States
7.6. EU4 and the UK
7.6.1. Diagnosed Cases of Antiphospholipid Syndrome in EU4 and the UK
7.6.2. Age-specific Cases of Antiphospholipid Syndrome in EU4 and the UK
7.6.3. Gender-specific Cases of Antiphospholipid Syndrome in EU4 and the UK
7.6.4. Type-specific Cases of Antiphospholipid Syndrome in EU4 and the UK
7.6.5. Clinical Manifestation-specific Cases of Antiphospholipid Syndrome in EU4 and the UK
7.6.6. Treated Cases of Antiphospholipid Syndrome in EU4 and the UK
7.7. Japan
7.7.1. Diagnosed Cases of Antiphospholipid Syndrome in Japan
7.7.2. Age-specific Cases of Antiphospholipid Syndrome in Japan
7.7.3. Gender-specific Cases of Antiphospholipid Syndrome in Japan
7.7.4. Type-specific Cases of Antiphospholipid Syndrome in Japan
7.7.5. Clinical Manifestation-specific Cases of Antiphospholipid Syndrome in Japan
7.7.6. Treated Cases of Antiphospholipid Syndrome in Japan
8. Appendix
8.1. Bibliography
8.2. Acronyms and Abbreviations
8.3. Report Methodology
9. DelveInsight Capabilities
 
10. Disclaimer

Antiphospholipid Syndrome (APS) - Epidemiology Forecast - 2034

DelveInsight's Antiphospholipid Syndrome (APS) - Epidemiology Forecast 2034 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Antiphospholipid Syndrome (APS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.